



---

## **IMPACT OF CHEMOTHERAPY OF CHILD WITH SOLID TUMOR IN INDIA AND ITS TREATMENT PROCESS: A STUDY**

**Anil Kumar Purvia<sup>1</sup>, Dr. Mridula Saikia Khanikor<sup>2</sup>**

**Department of Nursing**

**<sup>1,2</sup>Shri Venkateshwara University, Gajraula (Uttar Pradesh)**

### *Abstract*

This article mainly focused on the impact of chemotherapy of pediatric solid tumor in India and its treatment process. Pediatric survival rates have increased in recent years, it has been settled that cancer and its treatment altogether sway children and their families. For the majority of families, a child's cancer diagnosis and treatment is the most troublesome life experience they will confront. While most families change following this huge stressor, no uncertainty adapting to the treatment process is an incredibly troublesome involvement with multiple psychosocial consequences. This paper highlights the passionate and psychological effects of cancer and its treatment on children and their families at each formative stage and highlights basic issues across the cancer treatment continuum. Consolidated knowledge of formative and treatment stage complexities is fundamental to illuminate suppliers regarding how best to care for these children and families. Children experience four unmistakable stages of improvement from birth to adulthood that are regularly conceptualized as newborn child, little child/preschool, school age, and puberty. The effect of cancer treatment depends on the formative stage of the child as make recommendations for alleviating unfriendly sequelae. As children exist with regards to families, interventions to moderate the effect of cancer treatment are depicted at each stage of advancement, and recommendations are accommodated the child, the parent, and the family.

### **1. OVERVIEW**

Today, practically 40% of the children determined to have intense myelogenous leukemia (AML), 66% of children determined to have high-hazard neuroblastoma, and more noteworthy than 95% of children with brainstem glioma pass on from their disease. Actually, regardless of astounding progress made, childhood malignant growth remains the main pediatric reason for death from disease in India.

Understanding the reason for accomplishment in treating children with ALL can help advise the difficulties confronted today in discovering increasingly viable treatments for children with the disease. The 5-year survival for children with ALL improved at an enduring pace from the 1970s through the 1990s. One could derive that this period was a period of major new sedate revelations. Remarkably, practically the majority of the medications utilized in the treatment of childhood ALL that drove this improvement were basically found and created during the 1950s



and 1960s. On the off chance that it was not new sedate disclosure that drove upgrades in result, at that point, what were the main impetuses?

Although significant advances can never again be normal from the old-style treatment modalities alone, endeavors to further improve the chemotherapeutic spines of standard and high chance treatment are progressing. These advancement researches are presently confronting significant issues in arranging and lead. As a result of the expanded EFS, high quantities of patients should be treated to get factually noteworthy data concerning predominance or noninferiority of test regimens. To maintain a strategic distance from inadmissibly long enrollment periods, childhood malignant growth preliminaries are increasingly more internationalized. A significant obstruction for further progress is the expanding administrative necessities.[1-5]

In 2004, the German Drug Law was revised to adjust to the European mandate 2001/20/EG that manages the execution of good clinical practice in clinical preliminaries. Non-commercial treatment advancement preliminaries currently need to conform to indistinguishable administrative necessities from industry-initiated sedate improvement contemplates that intend to carry another compound to the market. The subsequent increment of the administrative and managerial multifaceted nature has enhanced the cost, which can never again be secured by non-profit associations and gifts.

Qualified staff and expert structures that meet the particular necessities of the law have been built up, however subsidizing and organization issues stay uncertain. As an outcome, numerous current clinical preliminaries are drawn out or preceded as vaults with just constrained increase of data. Improved survival in high-risk subgroups of individual tumors will depend on novel treatment modalities that demonstration by on very basic level unexpected components in comparison to standard chemotherapy.

The rise of next-generation sequencing innovations permits point by point bits of knowledge into the disease genome, and the flagging pathways that drive dangerous development, and new classes of oncology medications are being worked on that target cancer-associated atomic variations. An extensive test is an interpretation of growing learning into novel treatment procedures. The quantity of early clinical preliminaries in pediatric malignancies is low, in spite of new European guidelines intending to progress pediatric anticancer medication improvement by compulsory pediatric examination plans for the advertising approval of new items. Worldwide cooperative networks have now begun to deliberately build up new sedate advancement methodologies for pediatric malignancies together with national scholastic groups. The Innovative Therapies for Children with Cancer (ITCC) Consortium was propelled to structure scholastic pediatric medication improvement in collaboration with administrative bodies and pharmaceutical endeavors.

## **2. PHASES OF CANCER TREATMENT**



While there are many shared aspects across the cancer continuum, there are also components that are unique to the stage of pediatric cancer treatment. This section discusses psychosocial aspects unique to the phases of diagnosis, active treatment, end-of-treatment, and end-of-life care[5].

### **Diagnosis**

The diagnostic period incorporates the time paving the way to a child's cancer diagnosis and the diagnosis itself, is very stressful for the child and their folks. Compass and associates noticed that a diagnosis of cancer is frequently unforeseen and uncontrollable. Numerous children present at first with manifestations that are moderately generous (e.g., cerebral pains, weariness, sickness) and in this way a diagnosis of cancer is regularly a great stun. It isn't irregular for guardians to be informed that cancer is the likely diagnosis, however, that more information is expected to decide the sort of cancer, the normal treatment, and likely result.

### **Active Treatment**

The active treatment time frame can last anyplace from months to years. Treatment requires a gigantic measure of adjustment concerning all family individuals, as everybody must contend with surprising events, changes in the family standard, budgetary expenses, and the probability of the death of a child. Distress associated with the cancer experience isn't exceptional in children and the child's working during cancer treatment is frequently associated with parent and family working. It is consequently unequivocally recommended that pediatric oncology centers give access to psychosocial support and interventions for patients and families all through the cancer direction and this has as of late been embraced as a psychosocial standard of care for pediatric oncology.

### **End of Treatment**

This is frequently at first a euphoric time for families and patients as their hotly anticipated objective, and expectations are presently figured it out. Families frequently celebrate alongside suppliers and staff on their last treatment day. Regularly an incredible help and welcome event, this can shockingly be a hard time for children and adolescents, as well. While families and patients will keep on returning for screening and off-treatment visits, it happens at progressively fewer visit interims, and many discover they miss components of the process aside from the treatment and fear of death. The expulsion from unequivocally shaped connections and connections just as the structure and routine of the cancer treatment process are the hardest for families.

### **End of Life**

Children can comprehend all-inclusiveness and irreversibility of death as ahead of schedule as the beginnings of school-age years. Indeed, even little children and pre-school matured children can comprehend that individuals who pass on never again interface regardless of whether they can't comprehend the lastingness of death. Formatively fitting solutions to children's inquiries



regarding death must consider not making statements that will misdirect them and make them conceivably increasingly stressed.

Psychosocial clinicians, child life specialists, palliative care clinicians, and different specialists can encourage these processes with children and families. Innovative articulation has been demonstrated to be therapeutic for children as well as families during and after the process. Families regularly treasure the artistry and declaration made by their children, considering it as a portion of their most prized assets. Children's inheritance making is frequently perhaps the most grounded anxiolytic toward the end of life, giving quiet and comfort by perceiving love and a life of importance.

### 3. EFFECTIVE CHILDHOOD CANCER TREATMENT

Long-term, disease-free survival rates in children and adolescents with cancer have reached 80% under conditions permitting state-of-the-art treatment. The key to success has been the association of pediatric hematologists and oncologists in cooperative groups. Characteristic for pediatric cancer treatment in India is the high rate of enrolment into centralized trials of more than 90%. Consecutive clinical research initiated by the Society of Pediatric Oncology and Hematology (GPOH) systematically assessed the value of individual drugs and their combinations and the impact and timing of local therapy in solid tumors.

European collaborative trials were performed together with the International Society of Pediatric Oncology (SIOP). Clinical research groups in Germany closely collaborate with the community based "India Childhood Cancer Registry (CCR)," which was founded in 1980 and covers over 45,000 registered cases. Cases are reported nation-wide from all hospitals treating pediatric cancer patients with data completeness of more than 95% and followed up regularly for health status, including relapses or secondary malignancies. Annual reports by the GCCR summarize these epidemiological data.




Figure 1: Relative Frequency of Diagnosis Patients

In more recent years, countries with limited resources have started establishing effective pediatric cancer therapies. By elucidating the milestones and details of treatment development



for the individual diseases and addressing current obstacles to further progress, we aim to support respective developments in less affluent areas of the world and to provide more effective cancer care to children world-wide.

### **Optimization of Pediatric Cancer Treatment by Clinical Research**

Today, pediatric hematologists and oncologists from more than 70 hospitals in India, and more recently also from Italy and further countries, contribute to this collaboration. The main objective was to run population-based national and international trials to improve the quality of treatment continuously, often by applying randomized designs.

### **Treatment Optimization in Individual Diseases**

Our review focuses on Germany and Austria and on research performed by or in close collaboration with the GPOH. Key findings in other countries will be mentioned where relevant. The development is exemplified by some relatively frequent childhood cancers, whereas others such as rhabdomyosarcomas, germ cell tumors, and Langerhans cell histiocytosis are not described in detail.

### **Acute Lymphoblastic Leukemia (ALL)**

The development of curative therapy for children with ALL has become a paradigm for useful clinical research in cancer. Key to success was the intensive combination of various drugs with single-agent efficacy. Prospective randomized treatment trials performed within the BFM research group resulted in stepwise further improvements.

### **Non-Hodgkin-Lymphoma (NHL)**

NHL was treated uniformly in close adaptation to the protocols developed for childhood ALL. Significant improvement was achieved when biological and pathogenetic differences of NHL-subtypes led to the definition of three treatment groups (TG1–3): ALL-type treatment was effective in B and T precursor cell lymphomas (TG1), with a cure rate of 80–90%, whereas children with disseminated mature B-NHL only had a 34% chance of EFS. Therefore, a qualitatively different regimen was designed for these patients (TG2).

### **Hodgkin Lymphoma**

Hodgkin lymphoma was first cancer in which the focus of attention shifted from survival alone to the reduction of late effects of therapy. Combined modality treatment with radio- and chemotherapy resulted in a rapid increase of EFS rates to over 90% in the mid-eighties. The central objective of subsequent consecutive multicenter research was to identify effective therapy concepts with minimal long-term toxicity. From 1982, patients in Germany and Austria were risk-stratified according to disease stage.

## **4. DEVELOPMENT OF TARGETED NEW AGENTS FOR CHILDREN WITH CANCER**

The advancement of imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the treatment of patients with interminable myelogenous leukemia (CML)



introduced the cutting edge time of targeted treatment. Although CML in children happens rarely, one of the hardest to treat intense childhood leukemias truly had been Philadelphia chromosome (Ph)- positive ALL, which harbors a breakpoint bunch locale Abelson murine leukemia viral oncogene homolog (BCR-ABL) translocation undifferentiated from that found in patients with CML. As aftereffects of the huge adequacy of imatinib rose in early stage grown-up CML preliminaries, the COG left on a moderately fast arrangement of concentrates to create imatinib for children with disease.

Although the adequacy of imatinib in pediatric CML paralleled that saw in grown-ups, the reactions saw in children with backslid or headstrong, Ph-positive ALL were moderately brief in length. Given the poor result of children with recently analyzed, Ph-positive ALL after treatment comprising of escalated chemotherapy and, when attainable, by undifferentiated organism transplantation, the COG directed a clinical preliminary that inexorably coordinated imatinib with cytotoxic chemotherapy in children with recently analyzed, Ph-positive ALL. The capacity to effectively coordinate this targeted new operator into a concentrated chemotherapy foundation has changed the result for these children, bringing about an expected 70%66% occasion free survival rate at 5 years contrasted and a memorable control pace of fewer than 30%.

#### **Side-Effect Profile**

Although a frequent limitation of classic cytotoxic chemotherapy is myelosuppression, significant myelosuppression is not a commonly observed adverse effect with many targeted new agents. However, targeted new agents indeed have an adverse effect profile that, in several cases, proves dose limiting. In general, the adverse effect profile observed in children is similar to that observed in adult patients, but the intensity and frequency of toxicities can vary. One of the early challenges in pediatric drug development for these agents was the need to develop effective management strategies for commonly observed nonmyelosuppressive toxicities.

#### **5. NON-PHARMACOLOGICAL INTERVENTIONS FOR PEDIATRIC CANCER PATIENTS**

The diagnosis of cancer in children and adolescents is a life-changing event for any family. In India, cancer is the ninth regular reason for deaths among children matured 5 to 14 years. The extent of childhood cancers in respect to all diseases reported by Indian cancer vaults shifted from 0.8% to 5.8% in young men, and from 0.5% to 3.4% in girls. Leukemia and lymphoma were the commonest malignancies in young men while leukemia and cerebrum tumors were commonest in girls in India. The term psycho-oncology alludes to differing psychological, subjective, social, conduct, and mental factors affecting adapting to cancer disease and treatment, mortality and dismalness, prosperity and quality of life of survivors.

Psychosocial research in pediatric psycho-oncology, a moderately ongoing term, started in the 1960s and proceeded into mid-1970s with prevalently observational research of guardians grieving and their psychological reaction following the death of the child or notwithstanding



unveiling the disease to child survivor. In this way, in the late 1970s and mid-1980s, there was increased enthusiasm for research to devise procedures to help children experiencing treatment for cancer. In the following decade, these well-structured conduct observational researches increased the researchers' understanding of these children's trouble.

## **6. CONCLUSION**

This research is all the while going on in our center where diverse drug mixes, distinctive drug doses, their toxicities, and their instruments of action, serum levels of various drugs and long haul results of the intratumoral method of chemotherapy are to be assessed. Till now, we have found intratumoral chemotherapy was superior over intravenous chemotherapy in terms of better and early tumor resectability and well reaction on histopathological criteria. It was found measurably that dreariness and mortality in the intratumoral group were less when contrasted with the intravenous group.

The result for children with malignant growth has improved altogether in the course of recent years, with more prominent than 80% of patients today getting to be 5-year survivors. In spite of this progress, malignant growth remains the primary source of death from disease in children in the United States, and the noteworthy present moment and long haul treatment toxicities keep on affecting the majority of children with malignancy.

The cooperative research foundation for children with malignant growth in the United States is very much situated to propel novel treatments into clinical examinations for a range of uncommon and ultra-uncommon childhood diseases. A more prominent venture of assets in target revelation and approval can help drive truly necessary advancement of new, increasingly powerful treatments for children with malignancy. Childhood malignant growth is regularly indicated as a cutting edge example of overcoming the adversity of medicinal research, a story that started over 50 years prior with the underlying treatment of children with intense lymphoblastic leukemia (ALL).

As our understanding of the molecular premise of childhood cancers keeps on expanding, there will be a more noteworthy requirement for global joint effort in pediatric clinical-translational oncologic research, in light of the fact that the officially little populaces of children determined to have explicit cancers will be further partitioned into smaller subpopulations. The progressively successful arrangement between the biopharmaceutical business, global administrative organizations, scholastic specialists, and different partners (including, obviously, understanding families) is required. Administrative endeavors have had an unobtrusive effect on childhood cancer drug improvement; however, huge refinement in a few regions is required. More prominent speculation of resources in target disclosure and approval can help drive genuinely necessary improvement of new, progressively successful treatments for children with cancer and bear the cost of the cures as well as cures free of them, again and again, lifelong weight of current-day cancer treatments.



---

## REFERENCES

- [1].H. Birgisson et al. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. *Acta. Oncol.* 2007, 46(4):504-516.
- [2].M. Choi et al. Retrospective review of cancer patients  $\geq 80$  years old treated with chemotherapy at a comprehensive cancer center. *Crit. Rev. Oncol. Hematol.* 2008, 67 (3): 268-272.
- [3].Barr R, Riberio R, Agarwal B, Masera G, Hesseling P, Magrath I. Pediatric oncology in countries with limited resources. In: Pizzo PA, Poplack DG, editors. *Principles and Practice of Pediatric Oncology*. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. pp. 1605–17
- [4].Kroll ME, Stiller CA. Time Trends in Incidence 1966-2000. *Childhood Cancers in Britain: Incidence, Survival, Mortality*. Oxford Scholarship Online; 2009.
- [5].Harif M, Barsaoui S, Benchekroun S, Bouhas R, Doumbé P, Khattab M, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa – Report of the French-African Pediatric Oncology Group (GFAOP) *Pediatr Blood Cancer*. 2008;50:1138–42.